The Impact of Low Serum Magnesium Levels on COVID-19 Severity and Potential Therapeutic Benefits of Magnesium Supplementation: A Systematic Review.

Publication date: Jan 01, 2025

In this review, our objective was to analyze the association between serum magnesium (Mg) levels, Mg supplementation, and coronavirus disease 2019 (COVID-19) outcomes. This systematic review followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, searching major databases until February 2023. Twenty-six studies (11,363 patients) were included: 22 examining serum Mg levels (8474 patients) and four investigating Mg supplementations (2889 patients). Most studies indicated an association between lower serum Mg levels and increased COVID-19 severity, including higher mortality rates and prolonged recovery periods. Critical patients demonstrated significantly lower Mg levels compared to moderate/severe cases. However, some studies reported conflicting findings, with hypermagnesemia also associated with poor outcomes in specific patient populations. Regarding supplementation, higher dietary Mg intake correlated with shorter hospitalization duration and faster recovery. Mg supplementation exceeding 450 mg showed potential benefits, including increased antibody titers in pregnant women and reduced oxygen support requirements in elderly patients when combined with vitamins D and B12. While evidence suggests a potential relationship between Mg status and COVID-19 outcomes, findings are heterogeneous. Further investigation through well-designed clinical trials is required to gain deeper insights into the role of Mg in COVID-19 pathophysiology and the therapeutic potential of Mg supplementation.

Open Access PDF

Concepts Keywords
Coronavirus covid-19
February hypomagnesemia
Pathophysiology micronutrient supplementation
Pregnant serum magnesium
Vitamins severity of disease

Semantics

Type Source Name
drug DRUGBANK Magnesium
disease MESH COVID-19
drug DRUGBANK Oxygen
pathway REACTOME Vitamins
disease IDO role
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease IDO host
disease IDO pathogen
disease MESH infection
pathway REACTOME Immune System
disease MESH obesity
disease IDO blood
disease MESH thrombosis
disease MESH cardiovascular diseases
disease MESH inflammation
disease MESH oxidative stress
disease MESH cytokine storm
disease MESH disseminated intravascular coagulation
drug DRUGBANK Dacarbazine
disease MESH asymptomatic infection
disease MESH pneumonia
disease MESH respiratory failure
disease MESH death
disease MESH morbidity
disease MESH low blood pressure
disease MESH magnesium deficiency
disease MESH malnutrition
disease IDO process
drug DRUGBANK Methionine
disease MESH Communicable Diseases
drug DRUGBANK Parathyroid hormone
drug DRUGBANK Phosphate ion
drug DRUGBANK Iron
disease MESH Emergency
disease MESH acute kidney injury
disease MESH chronic kidney disease
drug DRUGBANK Tocilizumab
disease MESH arrhythmia
disease MESH abnormalities
disease MESH complications

Original Article

(Visited 1 times, 1 visits today)